173 related articles for article (PubMed ID: 19653263)
1. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
Grimminger P; Vallböhmer D; Hoffmann A; Schulte C; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R; Brabender J
J Surg Oncol; 2009 Nov; 100(6):447-51. PubMed ID: 19653263
[TBL] [Abstract][Full Text] [Related]
2. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.
Brabender J; Metzger R; Vallböhmer D; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Grimminger PP
Surgery; 2012 Feb; 151(2):306-12. PubMed ID: 21982526
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
4. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
5. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
7. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
[TBL] [Abstract][Full Text] [Related]
9. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.
Brabender J; Vallböhmer D; Grimminger P; Hoffmann AC; Ling F; Lurje G; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
J Gastrointest Surg; 2008 Nov; 12(11):1815-21. PubMed ID: 18769985
[TBL] [Abstract][Full Text] [Related]
11. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
Shen C; Hu L; Xia L; Li Y
Jpn J Clin Oncol; 2008 Nov; 38(11):770-6. PubMed ID: 18845519
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant radiochemotherapy in the treatment of esophageal squamous carcinoma:Preliminary results in a series of 15 patients].
Popescu I; Ionescu M; Ciurea S; Stănescu C; Gheorghe C; Anghel R; Croitoru A
Chirurgia (Bucur); 2003; 98(6):499-508. PubMed ID: 15143606
[TBL] [Abstract][Full Text] [Related]
13. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
14. Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers.
Hoffmann AC; Warnecke-Eberz U; Luebke T; Prenzel K; Metzger R; Heitmann M; Neiss S; Vallbohmer D; Hoelscher AH; Schneider PM
J Surg Oncol; 2007 Jan; 95(1):51-4. PubMed ID: 17066431
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].
Hölscher AH; Metzger R; Schneider PM
Zentralbl Chir; 2000; 125(4):319-25. PubMed ID: 10829311
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.
Vallböhmer D; Drebber U; Schneider PM; Baldus S; Bollschweiler E; Brabender J; Warnecke-Eberz U; Mönig S; Hölscher AH; Metzger R
J Surg Oncol; 2009 Jun; 99(7):409-13. PubMed ID: 19347901
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
[TBL] [Abstract][Full Text] [Related]
18. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
20. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Elsaleh H; Farrell JJ; Crane CH
J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
